55% Of This GoodRx Holdings Insider's Holdings Were Sold
55% Of This GoodRx Holdings Insider's Holdings Were Sold
From what we can see, insiders were net sellers in GoodRx Holdings, Inc.'s (NASDAQ:GDRX ) during the past 12 months. That is, insiders sold the stock in greater numbers than they purchased it.
从我们所见,内部人士在GoodRx Holdings, Inc.(纳斯达克:GDRX)过去12个月内是净卖出者。也就是说,内部人士出售的股票数量超过了他们购买的数量。
While we would never suggest that investors should base their decisions solely on what the directors of a company have been doing, we would consider it foolish to ignore insider transactions altogether.
虽然我们绝不会建议投资者仅仅依据公司的董事们所做的事情来做决定,但我们认为完全忽视内部交易是愚蠢的。
The Last 12 Months Of Insider Transactions At GoodRx Holdings
GoodRx Holdings过去12个月的内部交易
Over the last year, we can see that the biggest insider sale was by the Chief Accounting Officer, Romin Nabiey, for US$535k worth of shares, at about US$6.77 per share. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. It's of some comfort that this sale was conducted at a price well above the current share price, which is US$4.65. So it may not shed much light on insider confidence at current levels. Romin Nabiey was the only individual insider to sell over the last year.
在过去一年中,我们看到最大的内部人士出售是首席会计官Romin Nabiey出售了53.5万美元的股票,售价约为每股6.77美元。我们通常不喜欢看到内部人士出售股票,但出售价格越低,我们越担心。值得欣慰的是,这笔交易的价格远高于当前的股价,当前股价为4.65美元。因此,这可能不会太多影响当前水平下的内部人士信心。Romin Nabiey是过去一年中唯一出售股票的内部人士。
You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!
您可以在下面的图表中看到过去一年内内部交易(由公司和个人)所示情况。通过点击下面的图表,您可以查看每笔内部交易的详细信息!
If you are like me, then you will not want to miss this free list of small cap stocks that are not only being bought by insiders but also have attractive valuations.
如果你和我一样,那么你一定不想错过这份免费的关于小盘股票的名单,这些股票不仅被内部人买入,而且估值也很有吸引力。
Insider Ownership Of GoodRx Holdings
GoodRx Holdings的内部持股情况
I like to look at how many shares insiders own in a company, to help inform my view of how aligned they are with insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. Insiders own 3.3% of GoodRx Holdings shares, worth about US$57m. While this is a strong but not outstanding level of insider ownership, it's enough to indicate some alignment between management and smaller shareholders.
我喜欢查看公司内部人员拥有多少股份,以帮助我判断他们与公司内部人士的对齐程度。我认为如果内部人士在公司中持有大量股份,这通常是个好迹象。内部人士拥有GoodRx Holdings 3.3%的股份,价值约为5700万美元。尽管这是一种强而非特别突出的内部持股水平,但足以表明管理层与小股东之间存在一定的对齐关系。
What Might The Insider Transactions At GoodRx Holdings Tell Us?
GoodRx Holdings的内部交易可能告诉我们什么?
It doesn't really mean much that no insider has traded GoodRx Holdings shares in the last quarter. We don't take much encouragement from the transactions by GoodRx Holdings insiders. But it's good to see that insiders own shares in the company. Of course, the future is what matters most. So if you are interested in GoodRx Holdings, you should check out this free report on analyst forecasts for the company.
在过去的一个季度内没有任何内部人士交易GoodRx Holdings的股票,这实际上并没有太多意义。我们对GoodRx Holdings内部人士的交易并不感到兴奋。但看到内部人士在公司中持有股票是件好事。当然,未来才是最重要的。因此, 如果你对GoodRx Holdings感兴趣,你应该查看关于该公司的分析师预测的免费报告。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
如果你更愿意查看另一家公司——一家可能财务状况更优秀的公司——那么请不要错过这份有趣公司的免费列表,这些公司具有高投资回报率和低负债。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
在本文中,内部人士是指向相关监管机构报告其交易的个人。我们目前仅考虑公开市场交易和直接利益的私人处置,但不包括衍生交易或间接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?对内容有疑虑?请直接与我们联系。或者,发送电子邮件至 editorial-team (at) simplywallst.com。
这篇来自Simply Wall St的文章是一般性的。我们根据历史数据和分析师预测提供评论,采用无偏见的方法,我们的文章并不旨在提供财务建议。它不构成对任何股票的买入或卖出建议,也未考虑到您的目标或财务状况。我们旨在为您提供以基本数据驱动的长期分析。请注意,我们的分析可能未考虑最新的价格敏感公司公告或定性材料。Simply Wall St在提到的任何股票中均没有持仓。